Current Portfolio
Xilis
Micro-organoid technology for precision cancer therapy and improved drug discovery.
Xilis’s MOS technology preserves the cellular composition and biological richness of primary tissues, for more accurate and rapid predictions of efficacy and de-risking drug development from discovery to clinical trial.
Key Facts
- Sector
Life Sciences
- Country
United States
- Fund
LSP 6
- Entry
2021
- Website
- Xilis
- EQT Responsible Advisor
John de Koning
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.